Brief: Larimar Therapeutics Announces FDA Has Removed Partial Clinical Hold For Nomlabofusp Program In Friedreich’S Ataxia

Larimar Therapeutics

20/05/2024 21:47

May 20 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS ANNOUNCES FDA HAS REMOVED PARTIAL
CLINICAL
HOLD FOR NOMLABOFUSP PROGRAM IN FRIEDREICH’S ATAXIA
    * INTERIM DATA FROM OLE STUDY REMAINS ON TRACK FOR Q4 2024
    * BIOLOGICS LICENSE APPLICATION (BLA) SUBMISSION TARGETED
FOR 2H
2025
    * PLANS TO DOSE ESCALATE TO 50 MG FOLLOWING FURTHER
CHARACTERIZATION OF FRATAXIN PHARMACODYNAMICS (PD) AT 25 MG DOSE
    * ONGOING OPEN LABEL EXTENSION (OLE) STUDY INITIALLY
EVALUATING 25
MG

Source text for Eikon:  ID:nGNXbLCZjb 
Further company coverage:  LRMR.O 

 ((Reuters.Briefs@thomsonreuters.com;))